Pharmaceuticals
Pfizer says no major tornado damage to drug manufacturing areas of North Carolina facility
In this aerial image, damage is seen to a Pfizer pharmaceutical factory after a tornado hit the facility two days earlier, on July 21, 2023 in Rocky Mount, North Carolina. Sean Rayford | Getty Images Pfizer on Friday said there does not appear to be major damage to the drug manufacturing areas of its plant […]
Read More
Kenvue CEO says consumers are spending on brand-name health products even as they pull back in other areas
Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, speaks during an interview to celebrate its IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan Mcdermid | Reuters Most consumers have pulled back on spending as inflation squeezes their wallets, but they have not stopped paying up for brand-name […]
Read More
Ford’s dividend quality, J&J’s split-off, cost basis discipline — what we think about all these
Send your questions directly to Jim Cramer and his team of analysts at [email protected] . Reminder, we can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. Question 1: What are your thoughts on the stability of FORD’s dividend? Thank you, Denise The quickest […]
Read More
Johnson & Johnson investors can soon swap their shares for Kenvue stock — here’s what you need to know
Thibaut Mongon, CEO and Paul Ruh CFO of Kenvue Inc. a Johnson & Johnson’s consumer-health business, pose together during the company’s IPO at the New York Stock Exchange (NYSE) in New York City, U.S., May 4, 2023. Brendan McDermid | Reuters Johnson & Johnson on Thursday said its shareholders will soon be able to swap […]
Read More
J&J’s strong quarter was amplified by new details around its big Kenvue consumer unit stake
Johnson & Johnson (JNJ) reported strong second – quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. J & J’s second-quarter reported sales rose 6.3% year-over-year to $25.53 billion, exceeding the Refinitv consensus estimate of $24.63 billion. (On an adjusted […]
Read More
Kenvue earnings top estimates in J&J spinoff’s first quarterly report since IPO
Kenvue, a unit of Johnson & Johnson’s consumer health business. CFOTO | Future Publishing | Getty Images Kenvue reported second-quarter revenue and adjusted earnings that topped expectations Thursday in the consumer health company’s first quarterly report since it spun out from Johnson & Johnson two months ago. The company also issued an upbeat sales outlook […]
Read More
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations, and lifted its full-year guidance as sales from the company’s medtech business jumped. The medtech division provides devices for surgeries, orthopedics and vision. The company is benefitting from a rebound in demand for non-urgent surgeries among older adults, who […]
Read More
Pfizer Group B strep vaccine for infants returns encouraging mid-stage trial results
Streptococcus agalactiae bacteria, responsible for vaginal and urinary tract infections and newborn infections including meningitis and septicemia. Optical microscopy view. Cavallini James | BSIP | Universal Images Group | Getty Images Pfizer on Wednesday said its experimental vaccine targeting the potentially deadly bacterial disease Group B Streptococcus returned strong mid-stage clinical trial results, a promising […]
Read More
Johnson & Johnson sues Biden administration over Medicare drug price negotiations
Pavlo Gonchar | LightRocket | Getty Images Johnson & Johnson on Tuesday sued the Biden administration over Medicare’s new powers to slash drug prices, making it the third pharmaceutical company to challenge the controversial provision of the Inflation Reduction Act. The lawsuit filed in federal district court in New Jersey argues the Medicare negotiations violate […]
Read More
Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buyback
Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Bloomberg | Bloomberg | Getty Images Novartis shares jumped on Tuesday after the Swiss drugmaker raised its full-year guidance on strong drug sales and announced a $15 billion share buyback. The company […]
Read More